ThaddeusRexTollesonMDFACC FSCAI

PubMed

• 178 citations
  A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions: 12-Month Outcomes From ...
  Martin B. Leon, Laura Mauri, Jeffrey J. Popma, Donald E. Cutlip, Eugenia Nikolsky
  Journal of the American College of Cardiology. 2010-02-09
• 91 citations
  Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial
  Thaddeus R. Tolleson, J.Conor O’Shea, John A. Bittl, William B. Hillegass, Kathryn A Williams
  Journal of the American College of Cardiology. 2003-02-05
• 47 citations
  One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
  David E. Kandzari, Ajay J. Kirtane, Stephan Windecker, Azeem Latib, Elvin Kedhi
  Circulation. Cardiovascular Interventions. 2020-11-10

Journal Articles

• Clinical Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries: The RESOLUTE US Clinical...  
  Alan C. Yeung, Martin B. Leon, Ash Jain, Thaddeus R. Tolleson, Douglas J. Spriggs, Brent T. McLaurin, Jeffrey J. Popma, Peter J. Fitzgerald, Donald E. Cutlip,Joseph M...., J Am Coll Cardiol, 4/4/2011
• Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)  
  Tolleson TR, Newby LK, Harrington RA, Bhapkar MV, Verheugt FW, Berger PB, Moliterno DJ, White HD, Ohman EM, Van de Werf F, Topol EJ, Califf RM, SYMPHONY and the 2nd SY..., Am J Cardiol, 8/1/2003
• Relationship Between Heparin Anticoagulation and Clinical Outcomes in Coronary Stent Intervention: The ESPRIT Trial  
  Tolleson TR, O'Shea JC, Tcheng JE., Journal of the American College of Cardiology, 1/1/2003
• Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMP...  
  Batchelor WB. Tolleson TR. Huang Y. Larsen RL. Mantell RM. Dillard P. Davidian M. Zhang D. Cantor WJ. Sketch MH Jr. Ohman EM. Zidar JP. Gretler D. DiBattiste PM. Tchen..., Circulation, 1/1/2002
• Percutaneous Coronary Interventions in Anomalous Right Coronary Arteries Arising from the Left Sinus of Valsalva  
  Cohen MG, Tolleson TR, Peter RH, Sketch MH, Catheterization and Cardiovascular Interventions, 1/1/2002
• Increased Rates of Stent Thrombosis Among Patients with Acute Coronary Syndromes: Insights from Two Large Oral IIb/IIIa Antagonist Trials  
  Tolleson TR, Harrington RA, Newby LK, Berger PB, Van de Werf FD, Vahanian A, Fox KA, Moliterno DA, Califf RA, Topol EJ, Journal of the American College of Cardiology, 1/1/2002
• Intra-Arterial Thrombolysis and Abciximab for sub-acute Occlusion of the Distal Aorta accomplished by radial arterial access  
  Tolleson TR, De la Serna FR, Crowley JM, Stack RS, Zidar JP, Catheterization and Cardiovascular Interventions, 1/1/2001
• Highlights from the American Heart Association Annual Scientific Sessions  
  Tolleson TR, O'Shea JC, Bahit MC, Cabell C, Dyke CK, Kaul A, McGuire DK, East MA, American Heart Journal, 1/1/2001
• Relationship Between the Activated Clotting Time and Adverse Clinical Outcomes from ESPRIT/IMPACT II  
  Tolleon TR, Circulation, 1/1/2000
• Highlights from the American College of Cardiology 49th Annual Scientific Session  
  Tolleson TR, McGuire DK, O'Shea CO, Dyke DK, Kandzari DE, East MA, American Heart Journal, 1/1/2000
• Recent Clinical Trials in Acute Coronary Syndromes Without Persistent ST Elevation. Evidence-Based Guidelines  
  Tolleson TR, Harrington RH, Current Opinionin Cardiology, 1/1/1999
• Sudden Death in Young Athletes. Epidemiology, Causes, and Recommendations for Screening Programs  
  Tolleson TR, O'Connor CR, American Heart Journal, 1/1/1999
• Enhanced Thrombolysis, Reduced Coronary Reocclusion and Limitation of Infarct Size using Prostaglandin E1 in a Canine Thrombolysis Model  
  Feld S, Li G, Vaughn WK, Accad M, Tolleson TR, Swenson C, Ostro M, Smalling RW, Journal of the American College of Cardiology, 1/1/1994
• Join now to see all

Books/Book Chapters

• Textbook of Coronary Disease 
  Chapter: Adjunctive Therapies in Coronary Interventions 
  Tolleson TR, Harrington RA, Topol EJEditors: Serruys PW, Leon MB, Colombo A, Kutryk JB.Martin Dunitz Publishing2000
• Textbook of Interventional Cardiology – Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease 
  Chapter: The Role of Thrombosis in Acute Coronary Syndromes and Coronary Interventions 
  Tolleson TR, Harrington RHEditors: Lincoff AM, Topol EJ.The Humana Press, Inc1998

Abstracts/Posters

• Comparison of Measurement of Platelet Aggregation of Aggrastat, Reopro and Eptifibatide (The COMPARE study)
  Batchelor WA, Tolleson TR, Harrington RA, European Society of Cardiology, 5/1/2000

Lectures

• Anticoagulation Strategies in Acute Coronary Syndromes 
  ACC/I2 Interventional Summit 2006 New York, NY - 1/1/2006
• Evolution of Anticoagulation in PCI 
  The Medicine Co. National Training Seminar New York, NY - 1/1/2005
• Stent Thrombosis in Patients Undergoing PCI after Presenting with an Acute Coronary Syndrome 
  European Society of Cardiology-Stockholm, Sweden - 1/1/2001
• Scientific Session- Comparison of GP IIb/IIIa inhibitors on platelet aggregation in patients undergoing PCI 
  American College of Cardiology Anaheim CA - 1/1/2000
• Heparin Anticoagulation and Bleeding/Ischemic Events during PCI: The ESPRIT Trial 
  American Heart Association Scientific Session New Orleans - 1/1/1999
• Treatment strategies in acute coronary syndromes 
  University of Pittsburg Medical Center Grand rounds Pittsburgh, PA
• Join now to see all

Other

• Protective Effects of Glycoprotein IIb/IIIa Inhibitors in Patients with non-ST elevation Myocardial Infarction 
  Tolleson TR, Cor Therapeutics, Inc